Obsidian Personal Planning Solutions LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 21.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,872 shares of the company’s stock after purchasing an additional 501 shares during the period. Johnson & Johnson accounts for approximately 0.8% of Obsidian Personal Planning Solutions LLC’s investment portfolio, making the stock its 22nd biggest position. Obsidian Personal Planning Solutions LLC’s holdings in Johnson & Johnson were worth $507,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. DORCHESTER WEALTH MANAGEMENT Co boosted its stake in Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares during the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its stake in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. boosted its stake in Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares during the last quarter. Equitable Holdings Inc. boosted its stake in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd boosted its stake in Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the last quarter. 67.94% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.35% of the stock is owned by company insiders.
Analysts Set New Price Targets
Johnson & Johnson Trading Up 0.4 %
Shares of JNJ stock opened at $153.30 on Tuesday. The company’s fifty day simple moving average is $159.35 and its two-hundred day simple moving average is $167.49. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $186.69. The stock has a market capitalization of $399.24 billion, a price-to-earnings ratio of 22.74, a PEG ratio of 2.63 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.13 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.95%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 67.06%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 High Yields On Breakout Watch With Analyst Tailwinds
- Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
- 3 Financials The Insiders Are Buying
- Can Carnival Cruise Lines Set Sail For New Highs?
- If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
